TB-500 dosage: reported doses and schedule
A short piece of thymosin beta-4 with no proven repair benefit in humans.
Also called: TB500, Ac-LKKTETQ, Thymosin beta-4 fragment 17–23.
Healing and repair peptides · N-acetylated seven-amino-acid thymosin beta-4 fragment.
Typical reported dose: 2.5 mg twice a week
- Reported 2.5 mg twice weekly: 2.5 mg subcutaneously twice weekly twice weekly, under the skin. Reported by users, common report. Studied in: Adults reporting injury-recovery injections. (source)
- Reported daily 700 mcg: 700 mcg subcutaneously each evening once daily, evening, under the skin. Reported by users, occasional report. Studied in: An adult reporting quadriceps tendon pain. (source)
- Reported fragment 500 mcg twice daily: 500 mcg subcutaneously twice daily twice daily, under the skin. Reported by users, rare report. Studied in: An adult who explicitly called the product fragment 17–23. (source)
- Reported loading then less often: 5 mg per week for 4 weeks, then 2.5 mg every 2 weeks after that weekly for 4 weeks; then every 2 weeks, under the skin. Reported by users, occasional report. Studied in: An adult reporting knee pain and subcutaneous thigh injections. (source)
- Reported oral 500 mcg: 500 mcg orally once daily on an empty stomach once daily in the morning, by mouth. Reported by users, rare report. Studied in: A forum commenter describing a capsule plan. (source)
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Related to TB-500
- BPC-157: An experimental repair peptide with mostly animal evidence and a few small human reports.
- GHK-Cu: A copper-binding skin peptide with small topical studies and untested systemic injections.
- AHK-Cu: A copper peptide used in scalp serums, with laboratory findings and weak patent-only human data.
- Thymosin beta-4: A peptide studied for eye conditions and skin wounds; tendon-repair injections lack controlled human evidence.
- ARA-290: Experimental peptide studied for small-fiber nerve damage, with uncertain pain relief and safety.
- Ac-SDKP: An experimental repair peptide with old human studies, but no proven healing dose.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Cellulitis, NHS · NHS · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Federal Register: nonbinding draft HHS interim policy, October 30 2026, 2026
- HHS 503A peptide interim enforcement policy and conditions, October 30 2026, 2026
- July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for TB-500-Related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate), FDA · FDA · 2026
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026, FDA · FDA · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Thymosin Beta-4, Sport Integrity Australia · 2026
- Anaphylaxis, NHS · NHS · 2023
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.